-

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation

ST. LOUIS--(BUSINESS WIRE)--Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most.

From the medicine that keeps us healthy to the technology that connects and helps feed us, to the innovations that give us hope for the future—science has consistently driven progress and shapes every aspect of our lives. The campaign is inspired by the idea that science delivers more than solutions—it delivers breakthroughs that heal, protect, connect, and empower.

“Science Delivers” comes at a moment when misinformation threatens to undermine America’s innovation drive and the future of such breakthroughs. At a time of uncertainty, Bayer is committed to the idea that science is a method designed to test ideas, challenge assumptions, and build knowledge over time. The campaign encourages scientists, educators, media and citizens to learn how to spot misinformation and help push back against fearmongering and pseudoscience.

The campaign’s features include a Declaration on Science appearing in select newspapers, an interactive website to engage and become part of the movement, ads promoting the campaign, and oversized, interactive “Science, Sealed, Delivered” mailboxes at select events and locations, including most recently at the World Food Prize’s 2025 Borlaug Dialogue in Des Moines, Iowa.

At each mailbox, visitors are invited to scan a QR code and drop a digital postcard, delivering their own science moment— how science has sparked change, inspired hope, or powered progress in their lives and communities. These real stories are showcased on the newly launched ScienceDelivers.com, where Americans can explore a digital mosaic of testimonials, discover how science delivers, and learn more about the scientific process and how to identify credible evidence.

The Declaration on Science – “Don’t (Just) Trust the Science” – appears in the Wall Street Journal, Washington Times and Politico and affirms the importance of an evidence-based process conducted and reviewed by independent sources:

“We must strive to be healthier, more sustainable, and focused on what innovation can bring to improve society. We must celebrate science and continue every day to innovate. To find the next cure. To find the next breakthrough.”

In addition, as part of the campaign, a new video running nationally highlights key innovations made possible by science.

The “Science Delivers” campaign will give Americans a glimpse into scientific milestones that have transformed the way we live, work and care for ourselves and our planet.

Join Us and Share Your Support for Science:

Bayer encourages everyone to engage with the "Science Delivers" campaign by sharing their stories through social media and community events to champion science and its impact. Together, let us recognize the importance of science in our lives and advocate for its vital role in shaping a better future.

For more information on the "Science Delivers" campaign, visit www.ScienceDelivers.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media Contact:
Brian Leake
Brian.Leake@Bayer.com
(314) 370-3285

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Brian Leake
Brian.Leake@Bayer.com
(314) 370-3285

More News From Bayer

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026) – found that 82% worry about their own and their families' wellbeing due...

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC...

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor, which has the potential as a new approach to control the electrical activity of heart cells in patients with atrial fibrillation (AFib). The Phase II single-treatment study in a randomized, double-blind, placebo-controlled, parallel-group, mu...
Back to Newsroom